The purpose of this study is to compare the benefits and side effects of ABL001 versus bosutinib in subjects with chronic myelogenous leukemia (CML). CML is characterized by an abnormal chromosome called the 'Philadelphia chromosome'. The Philadelphia chromosome creates an abnormal protein (BCR-ABL) that causes some white blood cells (leukemia cells) to grow.
ABL001 is an investigational drug which has not been approved by the health authorities to date and is being developed to treat people with CML in chronic phase. Bosutinib is already approved by health authorities for your disease under the trade name Bosulif.
If you agree to join this study, you may be treated with either ABL001 or bosutinib. You have a 2 in 3 chance of being treated with ABL001 and a 1 in 3 chance of being treated with bostinib. You will be asked to take one 40mg tablet of ABL001 two times a day or one 500mg tablet of bosutinib once a day for up to 168 weeks.